FLARE-RA问卷临床相关切点的定义与结构效度验证
FLARE-RA 全局评分 AUC 为 0.71–0.92,病程 2–5 年患者临床检测与治疗变更切点分别为 2 和 5,病程>5 年患者分别为 2 和 3.5。
要点
- FLARE-RA 全局评分对 flare 的区分能力为可接受至优秀,AUC 0.71–0.92。
- 病程 2–5 年 RA 患者:临床检测切点 2,治疗变更切点 5。
- 病程>5 年 RA 患者:临床检测切点 2,治疗变更切点 3.5。
核心结论
- 所提出的 FLARE-RA 切点在所测试的锚定项间具有可接受的区分能力,预期有助于 RA flare 的早期识别和及时管理。
研究设计与样本
- 横断面研究,纳入法国(n=138)、丹麦(n=253)、美国(n=75)、阿根廷(n=105)门诊成人 RA 患者(2010 ACR/EULAR 标准)。
主要发现
- FLARE-RA 全局评分切点的区分能力为可接受至优秀,AUC 范围为 0.71 至 0.92。
- 使用「患者报告 flare」锚定项所得的 FLARE-RA 切点低于 DAS28-CRP 和「抗风湿治疗变更」锚定项。
关键数值与推荐
- 病程 2–5 年 RA 患者:临床检测切点为 2,抗风湿治疗变更切点为 5。
- 病程>5 年 RA 患者:临床检测切点为 2,抗风湿治疗变更切点为 3.5。
- 锚定项包括:患者报告 flare、DAS28-CRP>3.2、抗风湿治疗变更。
临床怎么用
- 可依据 RA 病程选用 FLARE-RA 切点辅助识别 flare:病程 2–5 年检测切点 2、治疗变更切点 5;病程>5 年检测切点 2、治疗变更切点 3.5。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire was devised for the detection of flares in patients with RA. We aimed to define construct validity and cut-off(s) for the FLARE-RA questionnaire. METHODS: This cross-sectional study included adult patients with prevalent RA (2010 ACR/EULAR criteria) attending outpatient rheumatology clinics in France (n = 138), Denmark (n = 253), USA (n = 75), and Argentina (n = 105). Flare occurrence over the past 3 months was assessed with the FLARE-RA questionnaire scoring from 0 (no flare) to 10 (maximum flare). The cut-offs for the FLARE-RA score were defined using the following anchor items obtained at the same encounter: (1) Patient report of flare; (2) DAS28-CRP > 3.2; (3) Change of anti-rheumatic treatment, based on the area under the receiver operating characteristic curve (AUC) and distance to (0,1). RESULTS: Four hundred seventy four patients with RA duration ≥2 years (mean age 58.6 years, 74.9% female) were included in the main analysis. The discrimination for the FLARE-RA cut-offs was acceptable-to-excellent: AUC for the global FLARE-RA score ranged from 0.71 to 0.92. The cut-offs for the FLARE-RA score were lower using "patient report of flare" than DAS28-CRP and "change of anti-rheumatic treatment". Proposed FLARE-RA cut-offs for clinical detection and change of anti-rheumatic treatment are 2 and 5, respectively, for patients with RA duration 2-5 years, and 2 and 3.5, respectively, for patients with RA duration >5 years. CONCLUSIONS: Proposed FLARE-RA cut-offs have acceptable discriminative capacity across the tested anchor items and are expected to aid in early recognition and timely management of RA flares.
引用
- Myasoedova E, De Thurah A, Erpelding ML, et al. Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire. Semin Arthritis Rheum. 2019. PMID: 31526593. doi:10.1016/j.semarthrit.2019.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。